Mon, Apr 21, 2014, 9:59 AM EDT - U.S. Markets close in 6 hrs 1 mins


% | $
Quotes you view appear here for quick access.

Xerox Corporation Message Board

shirley_ardell_mason 4 posts  |  Last Activity: Mar 4, 2014 11:03 AM Member since: Oct 3, 2002
  • Journal of Cardiovascular Pharmacology:
    February 2014 - Volume 63 - Issue 2 - p 85-94
    doi: 10.1097/FJC.0b013e318299ebc0
    Invited Review Article

    Cardiac Stem Cell Therapy: Review of the Native Cardiac Progenitor Cells and Future Direction

    Ye, Jianqin MD, PhD*; Yeghiazarians, Yerem MD*,†,‡


    Various stem cell types have been tested for regenerating damaged myocardium after myocardial infarction. However, the results of clinical trials have not been consistent, with only some of the trials reporting small improvements in cardiac function. It seems that engraftment and survival of injected cells is limited and transplanted stem cells either do not differentiate into cardiac cells or differentiate into only limited number of cardiac cells. The exact mechanism(s) of cardiac functional improvement by cell therapy are unclear, but paracrine effect may play a central role. The resident cardiac progenitor cells identified within the adult myocardium have distinct advantages over other stem cell types for cardiac cell therapy, as they are likely precommitted to the cardiovascular fate. However, isolating and expanding these cells from cardiac biopsies is a challenge. More recently, direct reprogramming of fibroblasts into cardiomyocytes has given new hope for myocardial regeneration. Here we will review different stem cells used in cardiac cell therapy with a focus on the native cardiac progenitor cells and briefly outline future directions of cardiac cell therapy.

  • shirley_ardell_mason shirley_ardell_mason Feb 17, 2014 11:25 AM Flag

    Japanese Institute Opens Investigation Into Its Stem-Cell Breakthrough

    Questions Have Been Raised About Images in Study

    A Japanese government-funded science institute said it has opened an investigation in response to questions raised about images in a groundbreaking study on stem cells.

    The Riken research institute said Monday that it began the investigation Thursday, following allegations of irregularities in images used in two papers published last month in the British journal Nature.

    The research, carried out by an international team led by Haruko Obokata of the Riken Center for Developmental Biology, found that mouse stem cells could be created by putting blood cells in a mild acid solution. If confirmed and extended to human cells, the technique could offer a safer and more ethical way to create stem cells and potentially help doctors use patient-specific stem cells in treating diseases. The Nature publication gathered global attention.

    Riken said the images in question include a photo of a placenta that the authors said was created from the new kind of stem cells, which they called STAP cells, for stimulus-triggered acquisition of pluripotency. On Internet forums such as PubPeer, a post-publication peer-review platform for scientists, some commenters said the same placenta image seemed to be used multiple times.

    Riken declined to offer more specifics regarding the assertions and said it started the investigation after an outside expert brought the matter to the institute's attention.

    A spokeswoman for Riken said a team of internal and outside experts is looking into the matter. She said they believe the Obokata team's findings remain valid. She said Ms. Obokata and other team members have been questioned and the results of the inquiry should be announced next month.

    Ms. Obokata couldn't be reached for comment.

    Ms. Obokata has received extensive publicity in Japan since the publication of her team's findings on Jan. 29.

  • Reply to

    Theta Risk And Reward, Excerpt From John Summa

    by eyt_trub Feb 13, 2014 8:31 AM
    shirley_ardell_mason shirley_ardell_mason Feb 13, 2014 9:52 AM Flag

    Silent killer and just steadily bleeding out. Either way the death rate is pretty high. Better to leg into a calendar spread. Tough to influence stock by pumping on message boards but for thinly traded options it is possible.

  • Scientists discover a new, simpler way to make stem cells

    By Carolyn Y. Johnson | Globe Staff January 29, 2014

    A team of Boston and Japanese researchers stunned the scientific world Wednesday by revealing a remarkably simple and unexpected way to create stem cells able to give rise to any tissue in the body.

    To transform mature cells into powerful stem cells that are a biological blank slate, the team simply bathed them in an acid bath for half an hour. The technique appears to be far easier and faster than current methods for creating these cells, which scientists are racing to develop into therapies for a range of diseases.

    The result is “shocking,” “astounding,” “revolutionary,” and “weird,” said scientists not accustomed to using such exuberant words to describe new research findings. The finding has been officially reported only in mice, but human studies are underway. Researchers at Brigham and Women’s Hospital said that over the weekend they made what appears to be a human version of the stem cells, although further study and confirmation of that preliminary result is needed.

    “It’s just a wonderful result; it’s almost like alchemy,” said Douglas Melton, co-director of the Harvard Stem Cell Institute, who was not involved in the research published Wednesday in the journal Nature. “It says one has found a way to reveal the hidden potential of cells with a relatively straightforward method.”

11.45+0.02(+0.18%)9:59 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.